{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-26-000039","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2026-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.845718+00:00","generated_at":"2026-05-15T07:29:20.703847+00:00","sec_items":["2.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Biogen warns of $34M pre-tax IPR&D and upfront charge in Q1 2026, impacting EPS by $0.19","bullets":["Preliminary estimate: ~$34M pre-tax acquired in-process R&D, upfront and milestone expense for Q1 2026.","Expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.19 per share.","Expense includes upfront/milestone payments and premiums on equity securities related to collaboration and license agreements.","Biogen does not forecast such costs due to uncertainty; final Q1 results not yet finalized and may differ."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-26-000039","json":"https://secwatch.observer/filing/0000875045-26-000039.json","markdown":"https://secwatch.observer/filing/0000875045-26-000039.md","text":"https://secwatch.observer/filing/0000875045-26-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504526000039/0000875045-26-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504526000039/biib-20260406.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:29:20.703847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe3f204dc365828a89af38a6a858ef4472c2e7ff","claim":"BIOGEN INC. reported preliminary financial results for the first quarter of 2026.","evidence_excerpt":"Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $34 million on a pre-tax basis.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875045/000087504526000039/0000875045-26-000039-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2026"},{"label":"Result","value":"preliminary results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}